The use of misoprostol in termination of second-trimester pregnancy

Taiwanese Journal of Obstetrics and Gynecology

Volumn 50, Issue 3, 2011, Pages 275-282

  Lin, Chen Ju ^a   Chien, Shu Chin ^b,c   Chen, Chih Ping ^a,b,d,e,f  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c Kanru Clinic   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Misoprostol; PGE1; Pregnancy; Second trimester; Termination

Indexed keywords

GEMEPROST; MIFEPRISTONE; MISOPROSTOL; OXYTOCIN; PROSTAGLANDIN F2 ALPHA;

ABDOMINAL CRAMP; ABDOMINAL PAIN; CHILL; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG UTILIZATION; FEVER; FLATULENCE; HEADACHE; HUMAN; LOADING DRUG DOSE; NAUSEA; PATIENT SELECTION; PEPTIC ULCER; PREGNANCY OUTCOME; PREGNANCY TERMINATION; REVIEW; SECOND TRIMESTER ABORTION; SECOND TRIMESTER PREGNANCY; SHIVERING; TERATOGENICITY;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTION, INDUCED; FEMALE; FETAL DISEASES; HUMANS; MISOPROSTOL; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS;

EID: 82455218995     PISSN: 10284559     EISSN: 18756263     Source Type: Journal    
DOI: 10.1016/j.tjog.2011.07.003     Document Type: Review

References (75)

1. Searle Cytotec (misoprostol) (information package) 1995, GD Searle & Co, Chicago.
2. Chong Y.S., Su L.L., Arulkumaran S. Misoprostol: a quarter century of use, abuse, and creative misuse. Obstet Gynecol Surv 2004, 59:128-140.
3. Foote E.F., Lee D.R., Karim A., Keane W.F., Halstenson C.E. Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function. J Clin Pharmacol 1995, 35:384-389.
4. Elati A., Weeks A.D. The use of misoprostol in obstetrics and gynaecology. Br J Obstet Gynecol 2009, 116:61-69.
5. Lumbiganon P., Hofmeyr J., Gulmezoglu A.M., Pinol A., Villar J. Misoprostol dose-related shivering and pyrexia in third stage of labour. WHO Collaborative Trial of Misoprostol in Management of the Third stage of labour. Br J Obstet Gynecol 1999, 106:304-308.
6. WHO WHO model list of essential medicine 2009, WHO, Geneva. 16th ed.
7. Agrawal N.M., Saffouri B., Kruss D.M., Callison D.A., Dajani E.Z. Healing of benign gastric ulcer. A placebo-controlled comparison of two dosage regimens of misoprostol, a synthetic analog of prostaglandin E1. Dig Dis Sci 1985, 30:164-170.
8. Hunt J.N., Smith J.L., Jiang C.L., Kessler L. Effect of synthetic prostaglandin E1 analog on aspirin-induced gastric bleeding and secretion. Dig Dis Sci 1983, 28:897-902.
9. Khan R.U., El-Refaey H. Pharmacokinetics and adverse-effect profile of rectally administered misoprostol in the third stage of labor. Obstet Gynecol 2003, 101:968-974.
10. Klitsch M. Antiprogestins and the abortion controversy: a progress report. Fam Plann Perspect 1991, 23:275-282.
11. New US food and drug administration labeling on Cytotec (misoprostol) use and pregnancy 2003, ACOG Committee Opinion 283, American College of Obstetricians and Gynecologists, Washington, DC.
12. WHO Safe abortion: technical and policy guidance for health system 2003, WHO, Geneva.
13. Li Y.T., Hou G.Q., Chen T.H., Chu Y.C., Lin T.C., Kuan L.C., et al. High-dose misoprostol as an alternative therapy after failed medical abortion. Taiwan J Obstet Gynecol 2008, 47:408-411.
14. Mao S.P., Chang C.C., Chen S.Y., Lai H.C. Gestational thrombocytopenia complicated with macrosomia, failure to progress in active labor, and postpartum hemorrhage. Taiwan J Obstet Gynecol 2007, 46:177-179.
15. Karim S.M.M. Once a month vaginal administration of prostaglandin E2 and F2α for fertility control. Contraception 1971, 3:173-183.
16. Rabe T., Basse H., Thuro H., Kiesel L., Runnebaum B. Effect of the PGE1 methyl analog misoprostol on the pregnant uterus in the first trimester. Geburtshilfe Frauenheilkd 1987, 47:324-331. [in German].
17. Norman J.E., Thong K.J., Baird D.T. Uterine contractility and misoprostol Y CME Review Article 137 induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 1991, 338:1233-1236.
18. Hsieh T.Y., Yu C.H., Kuo P.L., Chang F.M. Prenatal diagnosis of alobar holoprosencephaly with cystic hygroma. Taiwan J Obstet Gynecol 2006, 45:146-149.
19. Lin C.J., Weng S.L., Yeh L.F., Chen C.P., Su T.H. A comparison of intravaginal misoprostol administration with extra-amniotic foley traction using prostaglandin F2α infusion for termination of second-trimester pregnancy. Adv Obstet Perinatol 2000, 11:57-62.
20. Ferguson J.E., Burkett B.J., Pinkerton J.V., Thiagarajah S., Flather M.M., Martel M.M., et al. Intraamniotic 15(s)-15-methyl prostaglandin F2 alpha and termination of middle and late second trimester pregnancy for genetic indications: a contemporary approach. Am J Obstet Gynecol 1993, 169:332-340.
21. Lehair J., Lemarie P., Helleringer M., Manini P. Expulsion of arrested pregnancy product in the second trimester using a prostaglandin E1 analog administered intravaginally. Apropos of 12 cases. Rev Fr Gynecol Obstect 1989, 84:19-23.
22. Baird D.T., Norman J.E., Thong K.J., Glasier A.F. Misoprostol, mifepristone, and abortion. Lancet 1992, 339:13.
23. Bugalho A., Bique C., Almeida L., Faúndes A. The effectiveness of intravaginal misoprostol (Cytotec) in inducing abortion after eleven weeks of pregnancy. Stud Fam Plann 1993, 24:319-323.
24. Yapar E.G., Senoz S., Urkutur M., Batioglu S., Gokmen O. Second trimester pregnancy termination including fetal death: comparison of five different methods. Eur J Obstet Gynecol Reprod Biol 1996, 69:97-102.
25. Elsheikh A., Antsaklis A., Mesogitis S., et al. Use of misoprostol for the termination of second trimester pregnancies. Arch Gynecol Obstet 2001, 265:204-206.
26. Ashok P.W., Templeton A. Nin surgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. Br J Obstet Gynecol 1999, 106:706-710.
27. Ashok P.W., Templeton A., Wagaarachchi P.T., Flett G.M. Mid trimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception 2004, 69:51-58.
28. El-Refaey H., Templeton A. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens. Hum Reprod 1995, 10:475-478.
29. Ngai S.W., Tang O.S., Ho P.C. Randomized comparison of vaginal (200 μg every 3 h) and oral (400 μg every 3 h) misoprostol when combined with mifepristone in termination f second trimester pregnancy. Hum Reprod 2000, 15:2205-2208.
30. Tang O.S., Chan C.C., Kan A.S., Ho P.C. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation. Hum Reprod 2005, 20:3062-3066.
31. Hamoda H., Ashok P.W., Flett G.M., Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation. Hum Reprod 2005, 20:2348-2354.
32. Hou S., Zhang L., Chen Q., Fang A., Cheng L. One- and two day mifepristone-misoprostol intervals for second trimester termination of pregnancy between 13 and 16 weeks of gestation. Int J Gynecol Obstet 2010, 111:126-130.
33. Brouns J.F., van Wely M., Burger M.P., van Wijngaarden W.J. Comparison of two dose regimens of misoprostol for second-trimester pregnancy termination. Contraception 2010, 82:266-275.
34. Li Y.T., Hsieh J.C., Hou G.Q., Chen T.H., Chu Y.C., Lin T.C., et al. Simultaneous use of mifepristone and misoprostol for early pregnancy termination. Taiwan J Obstet Gynecol 2011, 50:11-14.
35. Li Y.T., Chen F.M., Chen T.H., Li S.C., Chen M.L., Kuo T.C. Concurrent use of mifepristone and misoprostol for early medical abortion. Taiwan J Obstet Gynecol 2006, 45:325-328.
36. Chai J., Tang O.S., Hong Q.Q., Chen Q.F., Cheng L.N., Ng E., et al. A randomized trial to compare two dosing intervals of misoprostol following mifepristone administration in second trimester medical abortion. Hum Reprod 2009, 24:320-324.
37. Jain J.K., Kou J., Mishell D.R. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Obstet Gynecol 1999, 93:571-575.
38. Ghorab M.N., El Helw B.A. Second-trimester termination of pregnancy by extra-amniotic prostaglandin F2alpha or endocervical misoprostol. A comparative study. Acta Obstet Gynecol Scand 1998, 77:429-432.
39. Dickinson J.E., Evans S.F. The optimization of intravaginal misoprostol dosing schedules in second-trimester pregnancy termination. Am J Obstet Gynecol 2002, 186:470-474.
40. Dickinson J.E., Evans S.F. A comparison of oral misoprostol with vaginal misoprostol administration in second-trimester pregnancy termination for fetal abnormality. Obstet Gynecol 2003, 101:1294-1299.
41. Bartley J., Baird D.T. A randomized study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. Br J Obstet Gynecol 2002, 109:1290-1294.
42. Wong K.S., Ngai C.S., Yeo E.L., Tang L.C., Ho P.C. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod 2000, 15:709-712.
43. Dickinson J.E., Godfrey M., Evans S.F. Efficacy of intravaginal misoprostol in second-trimester pregnancy termination: a randomized controlled trial. J Matern Fetal Med 1998, 7:115-119.
44. Wong K.S., Ngai C.S., Yeo E.L., Tang L.C., Ho P.C. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy. A randomized trial. Contraception 1998, 58:207-210.
45. Bebbington M.W., Kent N., Lim K., Gagnon A., Delisle M.F., Tessier F., et al. A randomized controlled trial of comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet Gynecol 2002, 187:853-857.
46. Tang O.S., Lau W.N., Chan C.C., Ho P.C. A prospective randomized comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. Br J Obstet Gynecol 2004, 111:1001-1005.
47. Bhattacharjee N., Saha S.P., Ghoshroy S.C., Bhowmik S., Barui G. A randomised comparative study on sublingual versus vaginal administration of misoprostol for termination of pregnancy between 13 to 20 weeks. Aust N Z J Obstet Gynaecol 2008, 48:165-171.
48. Carbonell J.L., Torres M.A., Reyes R., Ortega L., García-Gallego F., Sánchez C. Second-trimester pregnancy termination with 600-microg vs. 400-microg vaginal misoprostol and systematic curettage postexpulsion: a randomized trial. Contraception 2008, 77:50-55.
49. Caliskan E., Doger E., Cakiroglu Y., Corakci A., Yucesoy I. Sublingual misoprostol 100 microgram versus 200 microgram for second trimester abortion: a randomised trial. Eur J Contracept Reprod Health Care 2009, 141:55-60.
50. von Hertzen H., Piaggio G., Wojdyla D., Nguyen T.M., Marions L., Okoev G., et al. WHO research group on post-ovulatory methods of fertility regulation. Comparison of vaginal and sublingual misoprostol for second trimester abortion: randomized controlled equivalence trial. Hum Reprod 2009, 24:106-112.
51. Chaudhuri S., Banerjee P.K., Mundle M., Mitra S.N. A comparison of two regimens of misoprostol for second trimester medical termination of pregnancy: ad randomized trial. Trop Doct 2010, 40:144-148.
52. Cheng S.Y., Hsue C.S., Hwang G.H., Tsai L.C., Pei S.C. Hourly oral misoprostol administration for terminating midtrimester pregnancies: a pilot study. Taiwan J Obstet Gynecol 2010, 49:438-441.
53. Wildschut H., Both M.I., Medema S., Thomee E., Wildhagen M.F., Kapp N. Medical methods for mid-trimester termination of pregnancy. Cochrane Database Syst Rev 2011, 19:CD005216.
54. Lin M., Li Y.T., Chen F.M., Wu S.F., Tsai C.W., Chen T.H., et al. Use of mifepristone and sublingual misoprostol for early medical abortion. Taiwan J Obstet Gynecol 2006, 45:321-324.
55. Cheng S.Y., Chen T.C. Pilot study of labor induction with titrated oral misoprostol. Taiwan J Obstet Gynecol 2006, 45:225-229.
56. Gilbert A., Reid R. A randomised trial of oral versus vaginal administration of misoprostol for the purpose of midtrimester termination of pregnancy. Aust N Z J Obstet Gynaecol 2001, 41:407-410.
57. Cabrera Y., Fernández-Guisasola J., Lobo P., Gámir S., Alvarez J. Comparison of sublingual versus vaginal misoprostol for second-trimester pregnancy termination: a meta-analysis. Aust N Z J Obstet Gynaecol 2011, 51:158-165.
58. Dickinson J.E., Doherty D.A. Factors influencing the duration of pregnancy termination with vaginal misoprostol for fetal abnormality. Prenat Diagn 2009, 29:520-524.
59. Dilek T.U., Doruk A., Gozukara I., Durukan H., Dilek S. Effect of cervical length on second trimester pregnancy termination. J Obstet Gynaecol Res. 2011, 2:23-26.
60. Chou S.Y., Chen C.Y., Chiang H.K., Chow P.K., Wang C.C., Hsu C.S. Monitoring medical abortion using mifepristone/misoprostol combination with ultrasonogram and serum human chorionic gonadotropin. Taiwan J Obstet Gynecol 2006, 45:48-52.
61. Lalitkumar S., Bygdeman M., Gemzell-Danielsson K. Mid-trimester induced abortion: a review. Hum Reprod Update 2007, 13:37-52.
62. Dickinson J.E. Misoprostol for second-trimester pregnancy termination in women with a prior cesarean delivery. Obstet Gynecol 2005, 105:352-356.
63. Berghella V., Airoldi J., O'Neill A.M., Einhorn K., Hoffman M. Misoprostol for second trimester pregnancy termination in women with prior caesarean: a systematic review. Br J Obstet Gynecol 2009, 116:1151-1157.
64. Fawzy M., Abdel-Hady el-S. Midtrimester abortion using vaginal misoprostol for women with three or more prior cesarean deliveries. Int J Gynecol Obstet 2010, 110:50-52.
65. Mirmilstein V., Rowlands S., King J.F. Outcomes for subsequent pregnancy in women who have undergone misoprostol mid-trimester termination of pregnancy. Aust N Z J Obstet Gynaecol 2009, 49:195-197.
66. Winer N., Resche-Rigon M., Morin C., Ville Y., Rozenberg P. Is induced abortion with misoprostol a risk factor for late abortion or preterm delivery in subsequent pregnancies?. Eur J Obstet Gynecol Reprod Biol 2009, 145:53-56.
67. Ho P.C., Blumenthal P.D., Gemzell-Danielsson K., Gomez Ponce de Leon R., Mittal S., Tang O.D. Misoprostol for the termination of pregnancy with a live fetus. Int J Obstet Gynecol 2007, 99:178-181.
68. Dodd J., O'Brien L., Coffey J. Misoprostol for second and third trimester termination of pregnancy: a review of practice at the Women's and Children's Hospital, Adelaide, Australia. Aust N Z J Obstet Gynaecol 2005, 45:25-29.
69. Abdel-Aleem H., Villar J., Gulmezoglu A.M., Mostafa S.A., Yousef A.A., Shikry M., et al. The pharmacokinetics of the prostaglandin E1 analogue misoprostol in plasma and colostrum after postpartum oral administration. Eur J Obstet Gynecol Reprod Biol 2003, 108:25-28.
70. Gonzalez C.H., Vargas F.R., Perez A.B., Kim C.A., Brunoni D., Marques-Dias M.J., et al. Limb deficiency with or without Mobius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet 1993, 47:59-64.
71. Gonzalez C.H., Marques-Dias M.J., Kim C.A., Sugayamam S.M., Da Paz J.A., Huson S.M., et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 1998, 351:1624-1627.
72. Holmes L.B. Teratogen-induced limb defects. Am J Med Genet 2002, 112:297-303.
73. da Silva Dal Pizzol T., Knop F.P., Mengue S.S. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. Reprod Toxicol 2006, 22:666-671.
74. Adam M.P., Manning M.A., Beck A.E., Kwan A., Enns G.M., Clericuzio C., et al. Methotrexate/misoprostol embryopathy: report of four cases resulting from failed medical abortion. Am J Med Genet A 2003, 123:72-78.
75. Akdamar K., Agrawal N., Ertan A. Inhibition of nocturnal gastric secretion in normal human volunteers by misoprostol: a synthetic prostaglandin E1 methyl ester analog. Am J Gastroenterol 1982, 77:902-904.